workforce
Corporate courtship of nurses
When nurses are given financial
incentives by big pharma,
should we be concerned?
Emily Karanges interviewed by Conor Burke
N
ew data shows pharmaceutical
companies are increasingly
targeting non-prescribing
health professionals, such as nurses,
with financial gifts.
Payments to doctors by pharmaceutical
companies is commonplace and widely
accepted, and there is currently no
governmental regulation surrounding these
types of payments. But this new study
raises some ethical issues.
The University of Sydney has analysed
publicly available data of payments to
health professionals, submitted by the
pharmaceutical companies and submitted
to regulator Medicines Australia.
28 | nursingreview.com.au
Looking at the period between
October 2015 and April 2018, about
14,000 healthcare professionals received
over $62 million in payments from
pharmaceutical companies. Of that
number, about 18 per cent were nurses.
The study’s lead author, Dr Emily
Karanges, said: “There is a mistaken
idea that non-prescribing healthcare
professionals don’t have much influence
on medicine use, therefore their
pharmaceutical industry ties aren’t that
important. Yet healthcare professionals
like nurses and pharmacists often assist
with medication choice and encourage
adherence to treatment – and the roles
they play in chronic disease management
are expanding too.”
Karanges joined Nursing Review to
discuss her findings.
We saw about 40 per cent attendance
by nurses at these events. That’s partly why
we wanted to look into this a little more. It’s
an overlooked issue.
What is the form of these payments?
Does anyone get monetary payments?
The data encompasses just certain
payments. One is sponsored attendance
at conferences, where the registration
fees are paid. There might be travel
and accommodation given as well. So
obviously that’s not a physical payment.
But there are also payments for fees
for service. So, speaking at a conference,
participating on an advisory board, or
consulting services and the associated
travel and accommodation expenses.
NR: How did this research come about? Is this practice, for doctors or anyone
else, subject to any legal or health
department regulations?
EK: We have access to pharmaceutical
payment data on different healthcare
professionals, and we were seeing the
number of different health professionals
that were coming up in that data.
We’d also seen from other data in the
past that nurses and other healthcare
professionals attend a lot of company-
sponsored educational events. Most of the regulation is through the
pharmaceutical industry itself. They have
a code of conduct that regulates what
they’re allowed to do. For example, they
can’t fly an Australian to an Australian
conference in business class. They can
only do it economy. But, they can fly them
overseas in business class. They shouldn’t
be treating them to a meal over $120.